This year will be big for Duchenne muscular dystrophy (DMD) as interest in treatments is on the rise and deal activity is increasing, reported data and analytics company, GlobalData.
Year ahead 2018
“Mergers and acquisitions tend to bring in high revenues for drug deals and can indicate that a company has made a major investment into a certain therapy area,” explained Lisa Marris, healthcare analyst at GlobalData. “However, capital raising and strategic alliance transactions tend to be more numerous and provide the most insight into the climate of the DMD market.”